194 related articles for article (PubMed ID: 36982591)
21. The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer.
Liu C; Gao Y; Ni J; Chen S; Hu Q; Wang C; Hu M; Chen M
BMC Cancer; 2022 Jul; 22(1):788. PubMed ID: 35850679
[TBL] [Abstract][Full Text] [Related]
22. A Liquid-Liquid Phase Separation-Related Gene Signature as Prognostic Biomarker for Epithelial Ovarian Cancer.
Qiu Y; Pan M; Chen X
Front Oncol; 2021; 11():671892. PubMed ID: 34168991
[TBL] [Abstract][Full Text] [Related]
23. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
Zhao Y; Tao Z; Li L; Zheng J; Chen X
BMC Cancer; 2022 Mar; 22(1):239. PubMed ID: 35246070
[TBL] [Abstract][Full Text] [Related]
24. Identification and Validation of a Prognostic 5-Protein Signature for Biochemical Recurrence Following Radical Prostatectomy for Prostate Cancer.
Lv D; Cao Z; Li W; Zheng H; Wu X; Liu Y; Gu D; Zeng G
Front Surg; 2021; 8():665115. PubMed ID: 34136527
[No Abstract] [Full Text] [Related]
25. Identification of seven long noncoding RNAs signature for prediction of biochemical recurrence in prostate cancer.
Shao N; Zhu Y; Wan FN; Ye DW
Asian J Androl; 2019; 21(6):618-622. PubMed ID: 30860081
[TBL] [Abstract][Full Text] [Related]
26. Identification of molecular subtypes based on liquid-liquid phase separation and cross-talk with immunological phenotype in bladder cancer.
Sun L; Liu XP; Yan X; Wu S; Tang X; Chen C; Li G; Hu H; Wang D; Li S
Front Immunol; 2022; 13():1059568. PubMed ID: 36518754
[TBL] [Abstract][Full Text] [Related]
27. Lipid metabolism-related miRNAs with potential diagnostic roles in prostate cancer.
Zhai T; Dou M; Ma Y; Wang H; Liu F; Zhang L; Chong T; Wang Z; Xue L
Lipids Health Dis; 2023 Mar; 22(1):39. PubMed ID: 36915125
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Biological Significance of DNA Methylation-Driven Differentially Expressed Genes in Biochemical Recurrence After Radical Prostatectomy.
Luo C; He S; Zhang H; He S; Qi H; Wei A
Front Genet; 2022; 13():727307. PubMed ID: 35186021
[No Abstract] [Full Text] [Related]
29. Comprehensive analysis of the biological functions of endoplasmic reticulum stress in prostate cancer.
Cen S; Jiang D; Lv D; Xu R; Hou J; Yang Z; Wu P; Xiong X; Gao X
Front Endocrinol (Lausanne); 2023; 14():1090277. PubMed ID: 36967783
[TBL] [Abstract][Full Text] [Related]
30. A Five-LLPS Gene Risk Score Prognostic Signature Predicts Survival in Hepatocellular Carcinoma.
Lai W; Li D; Ge Q; Yan Y; Luo S; Lu Q
Int J Genomics; 2023; 2023():7299276. PubMed ID: 36873244
[TBL] [Abstract][Full Text] [Related]
31. Development and Validation of a Liquid-Liquid Phase Separation-Related Gene Signature as Prognostic Biomarker for Low-Grade Gliomas.
Ning L; Zhao G; Xie C; Lan H; Chen J; Tan H; Wei C; Zhou Z
Dis Markers; 2022; 2022():1487165. PubMed ID: 36193491
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of liquid-liquid phase separation-related genes in prediction of breast cancer prognosis.
Yu-Qing H; Peng-Ping L; Ke S; Ke-Xing Y; Wei-Jun Z; Zhen-Yu W
Front Genet; 2022; 13():834471. PubMed ID: 36246644
[No Abstract] [Full Text] [Related]
33. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
[TBL] [Abstract][Full Text] [Related]
34. Liquid-liquid phase separation throws novel insights into treatment strategies for skin cutaneous melanoma.
Liu J; Pei S; Zhang P; Jiang K; Luo B; Hou Z; Yao G; Tang J
BMC Cancer; 2023 May; 23(1):388. PubMed ID: 37127623
[TBL] [Abstract][Full Text] [Related]
35. A new risk stratification system of prostate cancer to identify high-risk biochemical recurrence patients.
Wu X; Lv D; Eftekhar M; Khan A; Cai C; Zhao Z; Gu D; Liu Y
Transl Androl Urol; 2020 Dec; 9(6):2572-2586. PubMed ID: 33457230
[TBL] [Abstract][Full Text] [Related]
36. Metabolic-related gene signature model forecasts biochemical relapse in primary prostate cancer.
Su Q; Liu Z; Zhu Y; Tian J
Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():65-68. PubMed ID: 36083923
[TBL] [Abstract][Full Text] [Related]
37. Identification of a Ubiquitin Related Genes Signature for Predicting Prognosis of Prostate Cancer.
Song G; Zhang Y; Li H; Liu Z; Song W; Li R; Wei C; Wang T; Liu J; Liu X
Front Genet; 2021; 12():778503. PubMed ID: 35111198
[No Abstract] [Full Text] [Related]
38. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
39. Identification and validation of a six immune-related gene signature for prediction of biochemical recurrence in localized prostate cancer following radical prostatectomy.
Luan J; Zhang Q; Song L; Wang Y; Ji C; Cong R; Zheng Q; Xu Z; Xia J; Song N
Transl Androl Urol; 2021 Mar; 10(3):1018-1029. PubMed ID: 33850736
[TBL] [Abstract][Full Text] [Related]
40. The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.
Chen L; Zheng Y; Jiang C; Yang C; Zhang L; Liang C
Front Immunol; 2022; 13():1009634. PubMed ID: 36275733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
